Lei YinMD

PhD in Economics from Southwest University of Finance and Economics.

He was  trading manager of China Minmetals Corporation, trading manager of Siemens, deputy general manager of Trade Finance Department of HSBC (Hong Kong). He joined CASI in 2006 and now serves as the MD of the company and a member of the future industry group. 

Mr. YIN led the investment of high-quality projects such as BeinMate (002570), NeuPharma, ExcelMab, StarryGene, Techfields and Resproly, etc.. He led the expansion of CASI’s innovative drug investment business, focusing on innovative drug development, gene technology and other medical fields.